TRIOMUNE (STAVUDINE/LAMIVUDINE/NEVIRAPINE) tablets are a fixed-dose combination antiretroviral therapy designed to treat HIV (Human Immunodeficiency Virus) infection in adults. Each tablet contains stavudine 30 mg, lamivudine 150 mg, and nevirapine 200 mg, working together to control HIV replication and support the immune system. TRIOMUNE is especially suitable for patients who have previously responded well to these individual drugs and can tolerate the recommended doses without adjustments.
HIV attacks CD4+ immune cells, weakening the immune system and increasing vulnerability to opportunistic infections. TRIOMUNE works by preventing the virus from replicating and integrating into the DNA of these immune cells. Stavudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that disrupt the viral DNA chain, while nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the viral enzyme reverse transcriptase. The combination ensures a dual mechanism of action that effectively lowers viral load, increases CD4+ counts, and helps maintain a healthier immune response.
Taking TRIOMUNE regularly as prescribed enhances compliance, reduces the risk of drug resistance, and helps maintain viral suppression. It should be taken consistently at the same time each day, and doses should not be skipped. While TRIOMUNE effectively slows HIV progression, it does not cure HIV or prevent transmission, so patients must continue other preventive measures.
Common side effects may include nausea, diarrhea, fatigue, rash, or headache. Patients should consult their healthcare provider if severe side effects occur. Regular monitoring of liver and kidney function, as well as blood counts, is recommended. TRIOMUNE tablets are available for safe purchase online in the USA, UK, and Canada through licensed pharmacies, providing convenient access for HIV management.
Primary Use: Treatment and management of HIV infection.